{"id":"NCT00835237","sponsor":"GlaxoSmithKline","briefTitle":"Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.","officialTitle":"Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02-17","primaryCompletion":"2009-07-23","completion":"2009-10-15","firstPosted":"2009-02-03","resultsPosted":"2010-08-05","lastUpdate":"2020-01-03"},"enrollment":1332,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Tetanus","Acellular Pertussis","Diphtheria","Diphtheria-Tetanus-acellular Pertussis Vaccines"],"interventions":[{"type":"BIOLOGICAL","name":"Boostrix®","otherNames":[]},{"type":"BIOLOGICAL","name":"Decavac™","otherNames":[]}],"arms":[{"label":"Boostrix Group","type":"EXPERIMENTAL"},{"label":"Decavac Group","type":"ACTIVE_COMPARATOR"}],"summary":"This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.","primaryOutcome":{"measure":"Number of Subjects With Antibody Concentration Against Vaccine Antigens, Above a Protocol Defined Cut-off Value","timeFrame":"One month after vaccination.","effectByArm":[{"arm":"Boostrix Group","deltaMin":729,"sd":null},{"arm":"Decavac Group","deltaMin":374,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":15},"locations":{"siteCount":24,"countries":["United States"]},"refs":{"pmids":["22212127"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":37,"n":887},"commonTop":["Pain","Fatigue","Headache","Redness","Swelling"]}}